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Purpose of the study
With the availability of new drug classes, the full suppres-
sion is a realistic goal even for heavily pre-treated patients.
We prospectively evaluated the magnitude of CD4 recov-
ery (CR) in this setting.
Methods
We decided to simultaneously screen triple class failing
patients (pts) followed at San Raffaele Hospital in three
Expanded Access Programs: raltegravir (MK0518-023),
maraviroc (A4001050), etravirine (TMC125-C214). Sal-
vage therapy was prescribed according to: viral tropism,
screening genotype and previous resistance tests. Data
were collected at baseline (BL) and at 4, 12, 24, 36 and 48
weeks. Generalized linear regression model was applied.
Results are reported as median (Q1–Q3).
Summary of results
Up to date, 68 pts reached week 24 (W24) without modi-
fication of the initial regimen; age 44.5 (41.7–49.9) years,
17 (25%) women, 10 (17.2%) IVDU, infected since 15.0
(12.5–18.4) years, ARV exposure of 13.0 (11.6–15.4)
years, CDC C stage 32 (47%). At BL: CD4 195 (87–306)
cells//μL; CD4% 11.8 (7.0–17.5), HIV-RNA 4.2 (3.8–5.0)
log10 copies/mL and CD4 nadir 73 (22–178) cells/μL. No
difference in BL characteristics were found according to
the group regimen prescribed. (Table 1.)
At week 24, 14 (93%), 13 (76%), 14 (74%), 15 (94%)
had HIV-RNA <50 copies/mL in group A, B, C, D, respec-
tively (p = 0.238).
At multivariable analysis, a significantly different CR was
related to therapy group (p = 0.035) and positively related
to BL HIV-RNA (p = 0.049). CR was higher in group A
(adjusted mean: 214.8 ± 37.3) than group B (129.2 ±
33.5, p = 0.062) or group C (115.7 ± 30.5, p = 0.023) or
group D (91.7 ± 33.3, p = 0.005). No independent effect
of age (p = 0.834), gender (p = 0.392), HIV risk factor (p
= 0.522), CD4% (p = 0.297) and CD4 nadir (p = 0.195)
was observed. Despite the high pill number, RAL
+MVC+ETR were very well tolerated; serious adverse
events were diagnosed in two pts: spondylodiscitis (one),
anal cancer (one).
Conclusion
Salvage therapy with RAL+ MVC+ETR showed an excellent
short-term CD4 recovery. Reasons for this success could
include: presence of active drugs blocking consecutive tar-
gets of viral replication, high doses of MVC required with
this regimen, avoidance of ritonavir and NRTI toxicity.
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N BL HIV-RNA BL CD4 W24 CD4
Group A: RAL+MVC+ETR 15 4.2(3.9–5.1) 276(90–528) 552(398–718)
Group B: RAL + MVC or ETR + PI sparing OBT** 17 4.0(3.9–4.7) 197(94–295) 378(330–447)
Group C: RAL + MVC or ETR +PI/r* based OBT** 20 4.7(3.8–5.3) 160(63–198) 306(239–361)
Group D: RAL + PI/r* based OBT** 16 4.2(3.6–4.9) 240(121–329) 349(276–504)
*in 33/36 darunavir/r **OBT = optimized background therapy.Page 2 of 2
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